Introduction {#s1}
============

The onset of psychosis is usually preceded by many years of multiple underlying abnormal biological processes ([@CIT0028]). One is the presence of increased proinflammatory and prooxidative status compared with normally developing individuals ([@CIT0057]; [@CIT0026]; [@CIT0045]). This imbalance seems to be present from the earliest stages of the disease ([@CIT0016]; [@CIT0041]; [@CIT0042]; [@CIT0013]; [@CIT0025]; [@CIT0032]), even before onset of pharmacological treatment ([@CIT0056]). Inflammation and increased oxidative stress could constitute a common pathway between early genetic and/or environmental factors (such as prenatal infections, obstetric complications, hypoxia, or stress during pregnancy) and the development of psychosis ([@CIT0021]; [@CIT0006]; [@CIT0034]). Exposure to inflammation during critical periods of brain development may affect processes such as cell differentiation, survival, and function ([@CIT0033]; [@CIT0059]) as well as contribute to sensitization of dopamine neurons ([@CIT0001]), which may predispose patients to earlier onset of neurodevelopmental illnesses such as schizophrenia and other psychoses ([@CIT0009]; [@CIT0008]).

Around 15% of patients with schizophrenia and other psychoses present with their first episode of psychosis before age 18 (early onset psychosis \[EOP\]) ([@CIT0004]). Patients with EOP seem to constitute a more developmentally impaired group and show greater negative symptom severity and increased risk for some negative outcomes than patients with later onset ([@CIT0005]; [@CIT0027]; [@CIT0014]). Young people with first episodes of EOP constitute an especially suitable population for assessing the potential role of inflammatory and oxidative processes on the development of psychosis, given their relative homogeneity in terms of potential confounding factors such as previous exposure to medication and the impact of inflammatory and oxidative processes on neurodevelopment. Additionally, considering that inflammatory alterations seem to be associated with poorer clinical and functional outcomes in patients with first episode psychosis (FEP) ([@CIT0024]; [@CIT0044]), information on the association between those alterations and clinical and neurobiological outcomes in EOP might be especially valuable, since it can provide support for targeted interventions with antioxidant and antiinflammatory strategies in this especially impaired subpopulation.

Two meta-analyses explored inflammatory ([@CIT0042]) and oxidative markers ([@CIT0021]) in patients with schizophrenia and reported increased levels of proinflammatory cytokines (i.e., interleukin \[IL\] 1-beta, IL-6, IL-12, interferon gamma, tumor necrosis factor alpha, tumor growth factor beta) and reduced levels of antioxidants (total antioxidant status \[TAS\], catalase \[CAT\], plasma nitrites, and superoxide dismutase \[SOD\]) in patients with FEP. However, few studies have specifically assessed oxidative and inflammatory markers in EOP and they have shown contradictory results ([@CIT0041]; [@CIT0023]).

Our goal was to review oxidative stress and inflammatory biomarkers at the peripheral level in subjects with first episodes of EOP and to explore the potential association of these parameters with clinical, cognitive, and other neurobiological measures, with a special focus on longitudinal outcomes.

Methods {#s2}
=======

Search Strategies {#s3}
-----------------

Using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, a systematic 2-step literature search was conducted to identify potentially relevant studies ([@CIT0051]). First, a PubMed search from inception through October 2016 was performed to detect studies comparing inflammatory and oxidative markers in patients with first episodes of EOP and healthy controls.

The initial search covered the combination of 2 concepts: 'early onset psychosis' (OR 'EOP' OR 'first-episode psychosis' OR 'FEP' OR 'early onset schizophrenia' OR 'first episode schizophrenia' OR 'early psychosis' OR 'early schizophrenia') AND 'inflammation' OR 'oxidation' (OR 'inflamm\*' OR 'inflammatory' OR 'anti-inflammatory' OR 'cytokine' OR 'interleukin' OR 'interferon' OR 'tumor necrosis factor' OR 'oxidat\*' OR 'oxidative'). Second, the reference lists of the selected articles were manually checked for any studies not identified by the computerized literature search.

Selection Criteria {#s4}
------------------

The initial literature search yielded 2468 studies. After removing duplicates, 604 potential studies were evaluated. All papers were double-screened in 4 phases with discrepancies resolved through discussion and consensus. In phase 1, the titles and abstracts of the retrieved papers were screened using the following hierarchical inclusion criteria: (1) they included patients with a diagnosis of EOP, early onset schizophrenia, FEP, early psychosis, or early schizophrenia; (2) they included a healthy control group; (3) they reported data on inflammatory and/or oxidative markers; (4) they included a minimum of 5 subjects in both the EOP and the control group; and (5) they were published in English as original peer-reviewed articles. Of the 604 studies, 139 fulfilled these inclusion criteria.

In phase 2, full text articles were comprehensively reviewed. Studies were excluded if they met any of the following hierarchical exclusion criteria: (1) they were not published as original peer-reviewed articles; (2) they did not include a healthy control group; (3) they did not include a first-episode EOP group (to consider this group as 'first episode' 'early onset psychosis group', all patients included in the study should be experiencing a first episode of psychosis according to DSM-III, DSM-IV, or DSM-IV-TR criteria and should be 18 years old or younger at the onset of psychosis; including brief psychotic disorder, psychotic disorder not otherwise specified, schizophreniform disorder, schizophrenia, mania with psychotic symptoms, and depression with psychotic symptoms; none of the reviewed studies included patients with substance-induced psychosis); and (4) they did not report data (mean and SD) either on inflammatory and/or oxidative markers or data on the statistical comparison of inflammatory and/or oxidative markers between EOP patients and controls. Of the 139 studies, 7 met none of the exclusion criteria and were thus available for the qualitative analysis ([@CIT0041]; [@CIT0023]; [@CIT0023]; [@CIT0039]; [@CIT0053]; [@CIT0052]; [@CIT0063]).

In phase 3, overlapping studies assessing the same inflammatory and/or oxidative markers in the same cohort were excluded to ensure that only independent samples were included in each of the meta-analyses. The following hierarchical criteria were used to determine the inclusion of overlapping studies: (1) study with the largest EOP group sample for the parameter of interest; (2) study with the largest control group sample for the parameter of interest; (3) most recent publication. Six of the 7 studies ([@CIT0041]; [@CIT0023]; [@CIT0039]; [@CIT0052], [@CIT0053]; [@CIT0063]) contributed with at least one marker and entered Phase 4.

Six separate meta-analyses were performed for inflammatory and/or oxidative markers with data available in at least 2 nonoverlapping studies (CAT, glutathione \[GSH\], glutathione peroxidase \[GPx\], SOD, TAS, and cell/DNA oxidative damage \[as linoleic acid hydroperoxides or 8-oxo-2'-deoxyguanosine, whose data were analyzed as equivalent ([@CIT0030]\]). Four studies contributed to the 6 independent meta-analyses ([@CIT0041]; [@CIT0023]; [@CIT0039]; [@CIT0053]). [Figure 1](#F1){ref-type="fig"} shows the PRISMA flow diagram of the systematic literature search strategy.

![PRISMA flow diagram of the systematic literature search strategy.](pyx01501){#F1}

Additionally, in the 7 studies selected for qualitative analysis, we reviewed associations between inflammatory/oxidative markers and baseline and/or longitudinal clinical, cognitive, functional, and other neurobiological variables.

Quality Assessment {#s5}
------------------

The quality of the 4 studies ultimately included in the meta-analyses was assessed using a checklist constructed specifically for this review, based on a previous meta-analysis on oxidative markers in schizophrenia ([@CIT0021]). Quality assessment was coded for each study on a scale of 0 to 10, with higher values meaning greater quality (details are given in supplementary Table 1).

Data Extraction {#s6}
---------------

Data extracted from eligible studies after Phase 4 included: name of inflammatory and/or oxidative marker; first author; location and year of the study; description of the study design; fasting status at blood extraction (as yes/no); study quality; and number of EOP patients, number of controls, mean and SD for each inflammatory and/or oxidative marker (for both EOP patients and controls), and/or statistical comparison of each marker between EOP patients and controls. The same data were extracted from studies assessing markers with insufficient data for performing a meta-analysis.

Additionally, putative moderating data from EOP patients, controls, or both, as appropriate, were extracted for markers included in the meta-analyses: mean age, sex (as percentage of male), diagnosis (as percentage of schizophrenia), mean body mass index (BMI), tobacco users (as percentage), cannabis use/abuse (as percentage), substance use/abuse (as percentage), exclusion of medical comorbidity (as yes/no), exclusion of NSAID/antiinflammatory drugs (as yes/no), mean duration of untreated psychosis, mean duration of untreated illness, antipsychotic naïve (as percentage), antipsychotic dose (as chlorpromazine equivalents), antipsychotic monotherapy (as yes/no), and antipsychotic name (if monotherapy).

Statistical Analysis {#s7}
--------------------

Data were entered into an electronic database and analyzed with a quantitative meta-analytical approach using Comprehensive Meta-Analysis Software version 3 (Biostat, Inc., Englewood, NJ).

Standardized mean differences (SMD) based on Hedges's adjusted *g* (SMD of -0.2 was considered small, -0.5 medium, and -0.8 large) and its 95% CIs were calculated for every individual marker. Based on the known heterogeneity of markers, we expected that the estimates would also vary substantially between studies. Random-effects models assume that the true effect size varies from one study to the next and, accordingly, are more conservative than fixed effect models. Therefore, random effects models by DerSimonian and Laird were used ([@CIT0012]).

Statistical heterogeneity was assessed through visual inspection of forest plots and using the *Q* statistic (a magnitude of heterogeneity) and the *I*^2^ statistic (a measure of the proportion of variance in summary effect size attributable to heterogeneity) ([@CIT0037]). Publication bias was assessed by visually inspecting funnel plots and using the Duval and Tweedie trim-and-fill method to estimate an effect size corrected for publication bias ([@CIT0017]).

Meta-regression using a random-effects model with unrestricted maximum likelihood was used to test effects of moderators on effect estimates. The slope of meta-regression line, β coefficient: direct (+) or inverse (−), indicates the strength of the relationship between moderator and outcome. Meta-regressions were planned when at least 5 studies were available for the moderator variable. Since the final number of included studies was lower, no meta-regressions could be performed.

To limit the risk of false positive (type I) errors arising from multiple comparisons, we adjusted the *P* value by dividing it by the number of meta-analyses conducted (corrected *P* = .0083 \[0.05/6\]).

For markers with a single study contributing data, SMD with 95% CI were also calculated and included in a separate table.

Results {#s8}
=======

Inflammatory and Oxidative Markers in EOP {#s9}
-----------------------------------------

Seven studies reported data on oxidative stress or inflammatory markers in EOP compared with healthy controls ([@CIT0041]; [@CIT0023]; [@CIT0023]; [@CIT0039]; [@CIT0053]; [@CIT0052]; [@CIT0063]). Details of these 7 studies are given in [Table 1](#T1){ref-type="table"}.

###### 

Characteristics of the Seven Studies Assessing Independent Oxidative and/or Inflammatory Data Identified in the Systematic Review

  **Author and Year**                      **Cohort**       **Biomarkers assessed**                                                                          **Included in the meta-analysis**   **N (EOP**)   **Age (mean), EOP**   **% Male, EOP**   **% Tobacco users, EOP**   **% SCZ, EOP**   **% AP naïve, EOP**   **DUP, EOP**   **N (C**)   **Age (mean), C**   **% Male, C**   **% Tobacco users, C**
  ---------------------------------------- ---------------- ------------------------------------------------------------------------------------------------ ----------------------------------- ------------- --------------------- ----------------- -------------------------- ---------------- --------------------- -------------- ----------- ------------------- --------------- ------------------------
  Fraguas et al., 2012                     Spain-CAFEPS     GSH                                                                                              No                                  48            16.0                  72.9              27.1                       56.3             na                    \<6 months     56          15.4                66.1            1.8
  Martínez- Cengotitabengoa et al., 2014   Spain-CAFEPS     GSH, TAS                                                                                         Yes                                 105           15.5                  67.6              30.5                       36.2             2.9                   \<6 months     97          15.2                64.9            6.2
  Mico et al., 2011                        Spain-CAFEPS     CAT, GPx, SOD, Oxidative damahe (LOOH)                                                           Yes                                 102           15.6                  66.7              na                         48               na                    \<6 months     95          15.3                64.2            na
  Parellada et al., 2012                   Spain-HGUGM      CAT, GPx, GSH, SOD, TAS, Hcy, TBARS, Uric acid, Albumin, Vit. B12, Vit. A, Vit. E, Transferrin   Yes                                 34            15.8                  67.6              na                         41.2             na                    na             34          12.8                94.3            na
  Simsek et al., 2016a                     Turkey-Dicle     GPx, SOD, Oxidative damage (8-oxo-dG), CoQ                                                       Yes                                 20            14.5                  40                na                         100              na                    na             20          14.4                40              na
  Simsek et al., 2016b                     Turkey-Dicle     IL-2, IL-4, IL-6, IL-10, TNF-alpha, IFN-gamma, IL-17 alpha                                       No                                  30            14.7                  43.3              na                         na               na                    na             26          14.5                33.3            na
  Xu et al., 2016                          China- Beijing   IL-18, IL-18R                                                                                    No                                  14            14.4                  50.0              na                         100              na                    na             13          13.5                53.8            na

Abbreviations: 8-oxo-dG, 8-oxo-2'-deoxyguanosine; AP, antipsychotic drug; C, control subjects; CAT, catalase; CoQ, coenzyme Q; DUP, duration of untreated psychosis; EOP, early onset psychosis; GPx, glutathione peroxidase; GSH, glutathione; Hcy, homocysteine (plasma); IFN-gamma, Interferon gamma; IL, interleukin; LOOH, linoleic acid hydroperoxides; na, not avalilable; SCZ, schizophrenia; SOD, superoxide dismutase activity; TAS, total antioxidant status; TBARS, thiobarbituric acid reactive substances; TNF-alpha, tumor necrosis factor alpha.

Meta-Analysis {#s10}
-------------

A total of 6 markers were addressed by 2 or more studies: CAT, GSH, GPx, SOD, TAS, and cell/DNA oxidative damage. Therefore, 6 meta-analyses were performed assessing these oxidative markers from 4 studies, comprising an overall sample of 261 EOP patients and 246 healthy controls, were performed. The mean age of EOP patients and controls ranged from 14.5 to 15.8 years and from 14.4 to 15.3 years, respectively. The percentage of male EOP patients and controls ranged from 40% to 67.6% and from 40% to 94.3%, respectively. Of the 261 EOP patients, 121 (46.4%) had a diagnosis of schizophrenia.

No significant differences were found between EOP patients and healthy controls in any of the oxidative parameters assessed. Heterogeneity among studies was high, with *I*^2^ values \>50%, except for CAT (with *I*^2^ of 5.3), (details of the results of the meta-analyses are shown in [Table 2](#T2){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}). Due to the small numbers of studies included for each parameter, no meta-regression analyses could be performed. Separate meta-analyses based on 2 papers ([@CIT0041]; [@CIT0053]) providing specific data on GPx and cell/DNA oxidative damage in EOP patients with a follow-up diagnosis of schizophrenia as compared with controls did not yield significant results either (SMD=1.34 (95% CI: -1.08 to 3.76), *P*=.279 for GPx, and SMD=1.37 (95% CI:-1.43 to 4,18), *P*=.338 for cell/DNA oxidative damage). The quality of the included studies was in general low (supplementary Table 1).

###### 

Main Results of the Meta-Analysis

  --------------------------------------------------------------------------------------------------------------------------------------
  **Random model**    **Effect size**   **Heterogeneity**                                                                        
  ------------------- ----------------- ------------------- ----- -------------------- -------- ------ -------- ------- -------- -------
  CAT                 2                 134                 127   -0.122 (-0.379 to\   -0.927   .354   1.056    0.304   5.316    0.003
                                                                  0.136)                                                         

  GPx\*               3                 124                 121   0.557 (-1.181 to\    0.628    .530   51.359   0.000   96.106   2.248
                                                                  2.295)                                                         

  GSH                 2                 130                 130   -0.240 (-0.694 to\   -1.038   .299   2.489    0.115   59.826   0.067
                                                                  0.214)                                                         

  Oxidative damage±   2                 94                  102   1.641 (-1.688 to\    0.966    .334   71.513   0.000   98.602   5.690
                                                                  4.971)                                                         

  SOD\*               3                 155                 147   -0.051 (-0.617 to\   -0.176   .860   8.830    0.012   77.350   0.190
                                                                  0.515)                                                         

  TAS                 2                 130                 130   -0.328 (-1.052 to\   -0.889   .374   6.023    0.014   83.397   0.229
                                                                  0.396)                                                         
  --------------------------------------------------------------------------------------------------------------------------------------

±Oxidative damage includes two different measures: LOOH and 8-oxo-dG.

\*Publication bias for GPx and SOD: Duval and Tweedie trim-and-fill, adjusted SMD= 0,557, (95% CI -1,181 to 2,295), adjusted Q= 51,359 for GPx; adjusted SMD= -0,051, (95% CI 0,617 to 0,515), adjusted Q=8,830 for SOD.

Abbreviations: 8-oxo-dG, 8-oxo-2'-deoxyguanosine; CAT, Catalase; EOP, Early Onset Psychosis; GPx, Glutathione Peroxidase; GSH, Glutathione; LOOH, Linoleic acid Hydroperoxides; SMD, standard mean difference; SOD, Superoxide Dismutase activity; TAS, Total Antioxidant Status.

![Forest plot of main results of the meta-analyses. CAT, catalase; GPx, glutathione peroxidase; GSH, glutathione; SOD, superoxide dismutase activity; TAS, total antioxidant status.](pyx01502){#F2}

Other Inflammatory and Oxidative Markers {#s11}
----------------------------------------

SMD between EOP and controls for markers with insufficient data for performing a meta-analysis are detailed in [Table 3](#T3){ref-type="table"}. Significant differences were found between EOP and controls in levels of IL 18 receptor (IL-18R1) ([@CIT0063]) and homocysteine ([@CIT0023]). No significant differences were found in the rest of the parameters assessed: albumin, thiobarbituric acid reactive substances, transferrin, uric acid, vitamin A, vitamin B12, vitamin E ([@CIT0023]), coenzyme Q ([@CIT0053]), interferon-gamma, IL-2, IL-4, IL-6, IL-10, IL-17 alpha, or tumor necrosis factor-alpha ([@CIT0052]).

###### 

Effect Size between EOP Patients and Controls for Markers Assessed by a Single Study

  **Marker**    **Study**                **N EOP patients**   **N controls**   **SMD (95% CI**)            **Z\***   ***P***
  ------------- ------------------------ -------------------- ---------------- --------------------------- --------- ------------
  Albumin       Parellada et al., 2012   34                   34               0.195 (-0.325 to 0.717)     0.737     .461
  CoQ           Simsek et al., 2016b     20                   20               -0.055 (-0.675 to 0.565)    -0.174    .862
  Hcy           Parellada et al., 2012   34                   34               1.620 (0.990 to 2.249)      5.042     **\<.001**
  IFN-gamma     Simsek et al., 2016a     34                   34               0.151 (-0.375 to 0.677)     0.562     .574
  IL-10         Simsek et al., 2016a     30                   26               -0.534 (-1.069 to 1.557)    -1.959    .050
  IL-17 alpha   Simsek et al., 2016a     30                   26               0.447 (-0.084 to 0.979))    1.649     .099
  IL-18         Xu et al., 2016          14                   13               0.368 (-0.393 to 1.130)     0.948     .343
  IL-18R        Xu et al., 2016          14                   13               -1.191 (-2.010 to -0.372)   -2.849    **.004**
  IL-2          Simsek et al., 2016a     30                   26               0.515 (-0.019 to 1.048)     1.890     .059
  IL-4          Simsek et al., 2016a     30                   26               0.073 (-0.452 to 0.598)     0.272     .786
  IL-6          Simsek et al., 2016a     30                   26               0.194 (-0.332 to 0.721)     0.723     .470
  TBARS         Parellada et al., 2012   34                   34               0.049 (-0470 to 0.569)      0.186     .852
  TNF-alpha     Simsek et al., 2016a     30                   26               0.301 (-0.227 to 0.829)     1.117     .264
  Transferrin   Parellada et al., 2012   34                   34               0.402 (-0.123 to 0.926)     0.150     .134
  Uric acid     Parellada et al., 2012   34                   34               0.378 (-0.146 to 0.902)     1.413     .158
  Vitamin A     Parellada et al., 2012   34                   34               0.381 (-0.143 to 0.906)     1.426     .154
  Vitamin B12   Parellada et al., 2012   34                   34               -0.347 (-0.817 to 0.176)    -1.300    .194
  Vitamin E     Parellada et al., 2012   34                   34               0.112 (-0.408 to 0.632)     0.423     .673

Abbreviations: CoQ, coenzyme Q; EOP, early onset psychosis; Hcy, homocysteine (plasma); IFN-gamma, interferon gamma; IL, interleukin; SMD, standard mean difference; TBARS, thiobarbituric acid reactive substances; TNF-alpha, tumor necrosis factor alpha.

Significant *P* values are bold.

\* A positive value means that marker is higher in EOP patients than in controls.

Association of Inflammatory and Oxidative Markers with Clinical, Cognitive, and Neurobiological Outcomes {#s12}
--------------------------------------------------------------------------------------------------------

Five studies reported data on the relationship between inflammatory and oxidative markers with clinical ([@CIT0041]; [@CIT0052], [@CIT0053]), cognitive ([@CIT0039]), and neuroimaging ([@CIT0023]) outcomes. Three studies explored the concurrent association between baseline oxidative and inflammatory markers and psychotic symptomatology ([@CIT0041]; [@CIT0052], [@CIT0053]). A significant negative correlation was found between levels of IL-4 and IL-10 and negative symptoms in one of the studies ([@CIT0052]) (details are shown on Supplementary Table 2). No significant associations were found between any baseline oxidative markers and clinical measures. Two studies found a significant association between baseline oxidative markers and gray matter loss ([@CIT0023]) and cognitive outcomes ([@CIT0039]) at 2-year follow-up (supplementary Table 2).

Discussion {#s13}
==========

The meta-analyses of first episodes of EOP and 6 antioxidant markers did not yield any significant results, with great heterogeneity among studies, and even opposite effects found for some markers in different studies. These contradictory findings might be due to some extent to great differences among samples, including differing assessment and analytical methods and clinical factors that might alter the levels of oxidative parameters, such as different exposure to antipsychotics ([@CIT0035]) or diagnosis. Additionally, most of the studies provided insufficient information or did not control for well-known confounding factors such as BMI or substance or tobacco use.

We did not replicate the findings of reduced antioxidant markers in adult-onset FEP from a previous meta-analysis based on 44 studies ([@CIT0021]). This could be due to the fact that all studies included in our meta-analyses assessed oxidative parameters in plasma in early onset of FEP, while most significant findings (except for TAS) in the previous meta-analysis were based on red blood cell markers in adult-onset FEP ([@CIT0021]). Moreover, even if all patients included in our meta-analysis were experiencing a first episode of EOP, there was moderate clinical heterogeneity. Clinical status may have affected state-related markers, such as TAS, CAT, and plasma nitrites, thereby affecting our findings. The finding of increased homocysteine and decreased IL-18R1 in patients with EOP is in agreement with previous findings in adult-onset psychosis ([@CIT0029]; [@CIT0046]; [@CIT0021]). Both markers could be involved in the pathophysiology of schizophrenia through their role in brain immune modulation, neuroinflammation, and neurodegeneration ([@CIT0040]; [@CIT0002]).

Increased levels of peripheral homocysteine have been associated with serum levels of complement component 4 (C4) ([@CIT0036]). The strongest genetic association described so far for schizophrenia affects the major histocompatibility complex locus ([@CIT0058]; [@CIT0049]). A recent genetic study suggests that this association might be due to genetic variation in C4 activity ([@CIT0050]), which could underlie unbalanced neuroinflammation processes with excessive stimulation of microglia ([@CIT0007]), leading to abnormal pruning of synapses during adolescence and early adulthood in people with psychosis. It could be speculated that increased levels of homocysteine could therefore indirectly reflect increased levels of C4. However, given that these findings are based on a single study, they should be appraised with caution, and future studies assessing the same markers are warranted.

Even though the meta-analyses did not find differences between EOP patients and controls in any of the markers assessed, some individual studies revealed an association of some oxidative and inflammatory parameters with some clinical dimensions at the first episode and longitudinal outcomes of the illness. Although these associations could not be specifically addressed in the meta-analyses, this suggests that greater inflammation and oxidative stress might lead to disturbed neural plasticity and increased neurodegeneration ([@CIT0038]), which could be associated with poorer outcomes in patients with FEP ([@CIT0024]). However, it should be noted that most of the putative associations with clinical variables assessed in cross-sectional studies at the first episode of an EOP were not significant, with only 2 cohorts finding a significant association between baseline inflammatory or oxidative stress biomarker levels and concurrent clinical or cognitive measures ([@CIT0041]; [@CIT0039]; [@CIT0052]), while findings of a significant association between baseline levels of antioxidants and gray matter loss and cognitive performance at follow-up were based on a single cohort ([@CIT0039]; [@CIT0022]). This highlights the need for further studies on the issue, especially on the potential effect of alterations in these biological parameters on longitudinal outcomes. Relatively small variance in symptomatic and functional variables among patients at the first episode might preclude finding significant associations that become evident during follow-up, facilitating the identification of subpopulations.

Results for some antioxidant and antiinflammatory agents in the management of schizophrenia are promising ([@CIT0055]). Interventions on the inflammatory and/or oxidative level seem to have a neuroprotective role ([@CIT0031]), comparable to the neuroprotective effect of cognitive therapy ([@CIT0018]; [@CIT0061]) or physical exercise ([@CIT0062]). However, antioxidant and antiinflammatory strategies for the treatment of psychosis still give conflicting results, with little evidence for their efficacy in the management of some psychopathological dimensions such as cognition ([@CIT0010]). The use of average values of inflammatory and oxidative markers for heterogeneous populations instead of using biomarkers to stratify patients may be one reason. Considering the intrinsic heterogeneity of psychotic disorders and the failure to identify biological markers for psychiatric disorders despite substantial effort ([@CIT0054]), alterations in inflammatory and oxidative markers could help identify subpopulations among EOP patients with different biological underpinnings that might also impact their prognosis ([@CIT0020]). That could, in turn, guide patient stratification and targeted interventions. This points to the need for stratification-based therapeutic strategies, as suggested by a recent trial assessing an antiinflammatory agent for management of treatment-resistant depression. The trial did not detect any significant efficacy in the complete sample but did find it to be efficacious in the subgroup of patients with high baseline levels of inflammatory markers ([@CIT0048]). Along those lines, a placebo-controlled RCT evaluating the efficacy of N-Acetylcysteine (NAC) in adult-onset FEP did not detect significant differences in any of the primary or secondary outcome measures between the placebo- and NAC-treated groups. However, NAC was found to significantly improve positive psychotic symptoms in the subgroup of NAC-treated patients with increased oxidative stress (increased levels of GPx) at baseline ([@CIT0015]). Stratification of patients based on baseline inflammatory or oxidative parameters, in accordance with personalized or precision medicine, could be especially indicated in EOP, where current treatment strategies fail to satisfactorily address some dimensions of the illness ([@CIT0022]).

This work was subject to several caveats. First, despite the extensive systematic literature review and the large number of papers initially identified, few articles could be included in the meta-analyses, and there was great heterogeneity among them. Furthermore, quality of the retrieved papers was not optimal, and most studies did not control for confounding factors such as BMI, tobacco, or substance use. This limits our capability to extrapolate the results of this meta-analysis and highlights the need for further studies on the issue, especially concerning inflammatory markers. Second, separate information based on diagnostic subgroups was not available for all the studies included in the meta-analyses. In this sense, we were only able to assess GPx and cell/DNA oxidative damage in EOP patients with a follow-up diagnosis of schizophrenia, with no significant differences between early onset schizophrenia subjects and controls. Considering that inflammatory and oxidative levels and their neurobiological impact might differ among EOP subpopulations ([@CIT0041]; [@CIT0023]; [@CIT0003]), future studies should assess the potential role of clinical diagnosis on this issue. Third, the impact of developmental stage on inflammatory and oxidative status in normally developing individuals is still understudied. The lack of replication of some of the previous findings in adults could be thus related to differential aspects of the inflammatory and oxidative mechanisms in younger people ([@CIT0060]). Studies assessing the impact of developmental stage on levels of inflammatory and oxidative parameters both in clinical and nonclinical populations are needed to appropriately appraise the potential role of these alterations in patients with EOP. Finally, although individuals with psychosis show increased cytokine levels in both peripheral blood and cerebrospinal fluid ([@CIT0042]), we only assessed peripheral biomarkers and these do not necessarily reflect the inflammatory and oxidative state of the brain. However, recent studies have found that cerebrospinal fluid levels of markers like IL-6 are significantly correlated with the plasma levels in patients with recent-onset schizophrenia ([@CIT0011]), suggesting that peripheral and central inflammatory systems probably operate in parallel in a synchronized way ([@CIT0019]).

Regardless of these limitations, this is to the best of our knowledge the first meta-analysis to specifically assess oxidative markers in patients with first episodes of EOP. We did not find consistent differences between EOP patients and healthy controls in any of the assessed parameters in the meta-analyses, possibly due to relative heterogeneity in the methods used and lack of consideration for potentially relevant factors such as diagnosis. In one of the cohorts assessed we did find a significant association between reduced levels of antioxidants and longitudinal outcomes, such as increased left frontal, left parietal, and left total gray matter loss and poorer cognitive performance at 2-year follow-up ([@CIT0023]; [@CIT0039]). This supports the role of oxidative alterations in the pathophysiology of EOP, or maybe in the pathophysiology of a subtype of psychosis ([@CIT0020]). That is, even if no differences might be detected in some parameters between EOP patients and controls, oxidative alterations might delineate a subgroup within EOP patients that shows poorer outcomes. This could lead to a personalized or precision clinical approach, help stratify patients, and have direct therapeutic implications by guiding targeted interventions with promising strategies such as antioxidants or antiinflammatory agents.
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